RxData
RxData provides pharmaceutical companies with comprehensive and up-to-date market access, pricing, and reimbursement data globally. Their platform enables faster, more informed decision-making by aggregating data from over 100 sources, offering insights into regulatory decisions, HTA publications, and list prices. With a focus on reducing research time and costs, RxData aims to give pharma companies a competitive edge through automation and real-time data access.
Industries
Nr. of Employees
small (1-50)
Products
Market-access and pricing intelligence platform
An online platform that aggregates global HTA, regulatory, reimbursement and price data, provides searchable indices, exportable dashboards, and algorithms to estimate net prices and forecast market outcomes.
Market-access and pricing intelligence platform
An online platform that aggregates global HTA, regulatory, reimbursement and price data, provides searchable indices, exportable dashboards, and algorithms to estimate net prices and forecast market outcomes.
Services
Cloud-delivered subscription providing access to a consolidated repository of HTA, regulatory, reimbursement and pricing data across multiple countries.
Project-based analytics including pricing forecasts, market-specific modelling and competitive landscape assessments to support licensing, launch and pricing strategy.
Cloud-delivered subscription providing access to a consolidated repository of HTA, regulatory, reimbursement and pricing data across multiple countries.
Project-based analytics including pricing forecasts, market-specific modelling and competitive landscape assessments to support licensing, launch and pricing strategy.
Expertise Areas
- Global market access and pricing intelligence
- Health technology assessment (HTA) curation
- Reimbursement tracking and analysis
- Price forecasting and market modelling
Key Technologies
- Real-time data aggregation and ETL pipelines
- Machine learning models for pricing analytics
- Price-estimation algorithms
- Cloud-based dashboards and export tools
News & Updates
RxData CEO Tommaso Albonetti presented new research and an updated model on using G-BA assessment data to model oncology pricing in Germany at the 2025 World EPA Conference in Amsterdam.
RxData CEO Lawrence Monoson presented research on determinants of price negotiations in Germany using Machine Learning at the 2024 World EPA Conference in Amsterdam.
Lawrence Monoson, CEO of RxData, discussed AIFA decisions in September 2023, including a favorable access decision for LUNSUMIO.
Discussion on the Inflation Reduction Act and its impact on drug price negotiations, a topic at the recent ISPOR conference.
RxData announced the launch of a new publication on patient-reported outcome measures at the World Evidence, Pricing and Access Congress in Amsterdam.
Insights and forecasts on oncology pricing in Germany using G-BA assessment data, presented by RxData CEO Tommaso Albonetti.
RxData CEO Tommaso Albonetti presented new research and an updated model on using G-BA assessment data to model oncology pricing in Germany at the 2025 World EPA Conference in Amsterdam.
RxData CEO Lawrence Monoson presented research on determinants of price negotiations in Germany using Machine Learning at the 2024 World EPA Conference in Amsterdam.
Lawrence Monoson, CEO of RxData, discussed AIFA decisions in September 2023, including a favorable access decision for LUNSUMIO.
Discussion on the Inflation Reduction Act and its impact on drug price negotiations, a topic at the recent ISPOR conference.
RxData announced the launch of a new publication on patient-reported outcome measures at the World Evidence, Pricing and Access Congress in Amsterdam.
Insights and forecasts on oncology pricing in Germany using G-BA assessment data, presented by RxData CEO Tommaso Albonetti.